Evidence map›Paper›PMID 37161048›Full record

ArticleCellular & molecular immunology2023

CTLA4 protects against maladaptive cytotoxicity during the differentiation of effector and follicular CD4

Yuwei Hao, Bahar Miraghazadeh, Rochna Chand, Ainsley R Davies, Chelisa Cardinez, Kristy Kwong, Morgan B Downes, Rebecca A Sweet, Pablo F Cañete, Lloyd J D'Orsogna and 11 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cellular & molecular immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Cytotoxic CD4Signal transduction and targeted therapy · 2026
    Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 4 institutions in 2 countries.

Yuwei HaoCentre for Personalised Immunology, John Curtin School of Medical Research, The Australian National University, Canberra, ACT, Australia.
Bahar MiraghazadehCentre for Personalised Immunology, John Curtin School of Medical Research, The Australian National University, Canberra, ACT, Australia.
Rochna ChandCentre for Personalised Immunology, John Curtin School of Medical Research, The Australian National University, Canberra, ACT, Australia.
Ainsley R DaviesCentre for Personalised Immunology, John Curtin School of Medical Research, The Australian National University, Canberra, ACT, Australia.
Chelisa CardinezCentre for Personalised Immunology, John Curtin School of Medical Research, The Australian National University, Canberra, ACT, Australia.
Kristy KwongCentre for Personalised Immunology, John Curtin School of Medical Research, The Australian National University, Canberra, ACT, Australia.
Morgan B DownesCentre for Personalised Immunology, John Curtin School of Medical Research, The Australian National University, Canberra, ACT, Australia.
Rebecca A SweetCentre for Personalised Immunology, John Curtin School of Medical Research, The Australian National University, Canberra, ACT, Australia.
Pablo F CañeteCentre for Personalised Immunology, John Curtin School of Medical Research, The Australian National University, Canberra, ACT, Australia.
Lloyd J D'OrsognaDepartment of Immunology, Fiona Stanley Hospital, Perth, WA, Australia.
David A FulcherDivision of Immunology and Infectious Diseases, John Curtin School of Medical Research, The Australian National University, Canberra, ACT, Australia.
Sharon ChooDepartment of Immunology, The Royal Children's Hospital, Melbourne, VIC, Australia.
Desmond YipDepartment of Medical Oncology, The Canberra Hospital, Canberra, ACT, Australia.
Geoffrey PetersDepartment of Medical Oncology, The Canberra Hospital, Canberra, ACT, Australia.
Sonia YipNHMRC Clinical Trials Unit, The University of Sydney, Sydney, NSW, Australia.
Matthew J WitneyDivision of Immunology and Infectious Diseases, John Curtin School of Medical Research, The Australian National University, Canberra, ACT, Australia.
Maxim NekrasovThe ACRF Biomolecular Resource Facility, John Curtin School of Medical Research, The Australian National University, Canberra, ACT, Australia.
Zhi-Ping FengANU Bioinformatics Consultancy, John Curtin School of Medical Research, The Australian National University, Canberra, ACT, Australia.
David C TscharkeDivision of Immunology and Infectious Diseases, John Curtin School of Medical Research, The Australian National University, Canberra, ACT, Australia.
Carola G VinuesaCentre for Personalised Immunology, John Curtin School of Medical Research, The Australian National University, Canberra, ACT, Australia.ORCID http://orcid.org/0000-0001-9799-0298
Matthew C CookCentre for Personalised Immunology, John Curtin School of Medical Research, The Australian National University, Canberra, ACT, Australia. mc2386@cam.ac.uk.ORCID http://orcid.org/0000-0002-3331-9363
Australian National University · AUFiona Stanley Hospital · AURoyal Children's Hospital · AUThe University of Sydney · AU

Funding

Cancer Australia 1130330Department of Health | National Health and Medical Research Council (NHMRC) 1113577
6 · The paper itself

Abstract

As chronic antigenic stimulation from infection and autoimmunity is a feature of primary antibody deficiency (PAD), analysis of affected patients could yield insights into T-cell differentiation and explain how environmental exposures modify clinical phenotypes conferred by single-gene defects. CD57 marks dysfunctional T cells that have differentiated after antigenic stimulation. Indeed, while circulating CD57

Indexed as

B-LymphocytesCD4-Positive T-LymphocytesCD57 AntigensCell DifferentiationCTLA-4 AntigenHumansCD57 AntigensCTLA-4 AntigenCTLA4 protein, humanCD57Cell exhaustionCTLA4Cytotoxic CD4+ T cellsImmunodeficiencyTerminal differentiation

Identifiers

PMID37161048
PMCPMC10166697
OpenAlexW4376114397

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.